Pidotimod
未知生产厂商
Pidotimod is a synthetic agent with immunomodulatory properties used in patients with documented cell-mediated immunosuppression to stimulate their immunity during lung and urinary tract infections.
Pidotimod is a synthetic agent with immunomodulatory properties used in patients with documented cell-mediated immunosuppression to stimulate their immunity during lung and urinary tract infections.
Pidotimod inhibits tumor necrosis factor α (TNF-α) induced increases in extracellular signal-related kinase (ERK) phosphorylation . It also increases nuclear factor κB (NFκB) expression and translocation to the nucleus. It is these to modulatory effects on ERK and NFκB signalling which are thought to produce the increase in toll-like receptor expression seen with pidotimod. Pidotimod increase maturation of dendritic cells responsible for presenting antigens to naive Th-cells . It also appears to result in a greater population these cells diiferentiating to Th1 cells which are believed to mediate the immune response to pathogens like bacteria and viruses . Lastly, pidotimod appears to increase antigen-specific antibody titer and cytotoxic response with antigen exposure . The precise mechanism and timeline of events leading to these effects is unknown.
For use as immunostimulant therapy for treatment of cell-mediated immunosuppression with respiratory or urinary infections .
共 1 项相关疾病
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。